{"_wandb":{"runtime":14},"study_name":"Study from Pons-Tostivint 2023.pdf","extracted_data":{"file_name":"Pons-Tostivint 2023.pdf","treatment_regimens":["pembrolizumab alone (IO-mono)","pembrolizumab in combination with platinum-based chemotherapy (CT-IO)"],"countries":["France"],"populations":[{"pdl1_status":"PD-L1 ≥ 50%","n":243,"stage, histology":"Stage III (not amenable to curative treatment) or Stage IV, non-squamous NSCLC"},{"pdl1_status":"PD-L1 ≥ 90%","n":59,"stage, histology":"Stage IV, non-squamous NSCLC"},{"stage, histology":"Stage IV, non-squamous NSCLC","pdl1_status":"PD-L1 50-89%","n":82},{"n":26,"stage, histology":"Locally advanced, non-squamous NSCLC","pdl1_status":"PD-L1 ≥ 50%"},{"pdl1_status":"PD-L1 ≥ 50%","n":115,"stage, histology":"Metastatic, non-squamous NSCLC"}],"results":{"group_difference":"no difference was observed between groups (p=0.51)","pembrolizumab alone (IO-mono)":{"median_os":"not reached","os_12_month":"66.1%","median_rw_pfs":"10.6 months"},"pembrolizumab in combination with platinum-based chemotherapy (CT-IO)":{"os_12_month":"70.2%","median_rw_pfs":"11.3 months","median_os":"not reached"}},"study_name":"Study from Pons-Tostivint 2023.pdf"},"status":"success","_timestamp":1.742680017818232e+09,"_runtime":14.873789,"_step":0}